Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). METHODS: Eligibility requirements were Karnofsky performance status ≥60%; no concurrent hepatic enzyme-inducing anticonvulsants; p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Lassman, Andrew B., Pugh, Stephanie L., Gilbert, Mark R., Aldape, Kenneth D., Geinoz, Sandrine, Beumer, Jan H., Christner, Susan M., Komaki, Ritsuko, DeAngelis, Lisa M., Gaur, Rakesh, Youssef, Emad, Wagner, Henry, Won, Minhee, Mehta, Minesh P.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2015
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762006/
https://ncbi.nlm.nih.gov/pubmed/25758746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov011
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky